TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01322880

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Discussion sessions
Description: Those selected were invited to attend a 6 session course on household decision-making with their spouses. Topics included budgeting, household financial management, and negotiation skills

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Village Savings and Loans Associations
Description: The approach developed by CARE International develops Village Savings and Loan Associations (VSLAs). A VSLA is a self-selected group of people who pool their money into a fund from which members can borrow. The money is paid back with interest, causing the fund to grow. The regular savings contributions to the Association are deposited with an end date in mind for distribution of all or part of the total funds (including interest earnings) to the individual members, usually on the basis of a formula that links payout to the amount saved. This lump sum distribution provides a large amount of money that members can then use as they want, without restriction.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Village Savings and Loans Associations
Description: The approach developed by CARE International develops Village Savings and Loan Associations (VSLAs). A VSLA is a self-selected group of people who pool their money into a fund from which members can borrow. The money is paid back with interest, causing the fund to grow. The regular savings contributions to the Association are deposited with an end date in mind for distribution of all or part of the total funds (including interest earnings) to the individual members, usually on the basis of a formula that links payout to the amount saved. This lump sum distribution provides a large amount of money that members can then use as they want, without restriction.
Study: NCT01987765

Intervention type: DRUG
Intervention: Relestat Ophthalmic Solution 0.05%
Description: Relestat Ophthalmic Solution 0.05% prescribed as local standard of care in clinical practice.
Study: NCT01811758

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally Specific CBT

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard CBT
Study: NCT04514939

Intervention type: OTHER
Intervention: Elevation of the legs during bed rest
Description: Patients of Group A will will lie in their hospital bed with a moderate leg elevation (between 15 and 30 degrees)
Study: NCT01190865

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: HP802-247
Description: One dose of HP802-247 consisting off 260 mL containing keratinocytes and fibroblasts totaling 5.0 x 10.6 cells per mL, plus fibrin.
Study: NCT00824291

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: desvenlafaxine succinate sustained release
Description: 50 mg/day oral tablet for 12 weeks

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genotyping
Description: CYP2D6 genotyping at randomization
Study: NCT02092363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMP-54F28, Paclitaxel and Carboplatin
Study: NCT00222118

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: labor/birth preparation classes
Description: prenatally, peer counselor/advanced practice nurse team, hospital visit, peer counselor telephone support for 4 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intervention
Description: prenatal classes and phone calls from peer counselor, peer counselor/lactatin consultant, hospital visit, telephone support to 4 weeks postpartum

Intervention type: OTHER
Group type: OTHER
Intervention: usual care
Description: no intervention
Study: NCT00829790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline Monohydrate
Description: 25 mg 5mL oral dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline Monohydrate
Description: 25 mg 5 mL dose
Study: NCT00545792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: Avastin will be administered intravenously (vein) at 10mg/kg every two weeks starting day 1 for a total of 3 doses.
Study: NCT02208128

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Sunitinib, Pazopanib, Bevacizumab, Everolimus...
Description: Clinical standard
Study: NCT04369937

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT (Intensity Modulated Radiotherapy)
Description: Radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: A potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between programmed cell death protein 1 (PD-1) and its ligands, PD-L1 and PD-L2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Chemotherapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISA101b
Description: ISA101b is a therapeutic cancer vaccine that induces specific immune responses to the oncogenic E6 and E7 antigens from HPV16.
Study: NCT02561520

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP eye drops
Description: Eye drops 4x a day, patients will start this eye drop first.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PPP eye drops
Description: Eye drops 4x a day, patients will start this eye drops after PRP.
Study: NCT00968812

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Glimepiride will be given orally (by mouth), as over-encapsulated tablets, starting at a dose of 1mg once daily and increasing to a maximum of 6 mg or 8 mg once daily for 104 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin (JNJ-28431754)
Description: Canagliflozin (JNJ-28431754) will be given orally as over-encapsulated tablets, at a dose of 100 mg or 300 mg once daily for 104 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin (JNJ-28431754)
Description: Canagliflozin (JNJ-28431754) will be given orally as over-encapsulated tablets, at a dose of 100 mg or 300 mg once daily for 104 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin will be given orally at the protocol-specified dose for 104 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin will be given orally at the protocol-specified dose for 104 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin will be given orally at the protocol-specified dose for 104 weeks.
Study: NCT01831362

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focused Attention (FA)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Open- Monitoring
Study: NCT03003091

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Needs-based patient education

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional patient education
Study: NCT03341182

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluoroscopically Guided Lumbar Transforaminal Epidural Injections
Description: Lay the subject down on the stomach and hold the pillow on the stomach. The skin of the injection area is sterilized by aseptic method and covered with aseptic pouch. After confirming the level of he vertebrae around the C-arm and aligning the anteroposterior view of the endplate of the vertebral body, rotate the C-arm 20\~30 degrees diagonally in the direction to be performed. After confirming the best Scotty dog view, confirm the final target point at 6 o'clock directly below the pedicle. At this position, the skin point is marked on the skin. And then both groups proceed in parallel with the beam direction of the transducer with the tunnel view technique until the needle reaches the back of the vertebral body at the level of the spinal nerve roots. At this time group A uses a mirror and group B dose not. The final reach of the target point (ideal depth) is confirmed through the anterior and posterior views and lateral views.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional manner
Description: A portable mirror is located at the side of surgical table and used in this procedure.
Study: NCT01001403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nafamostat
Description: 0.2 mg/kg as bolus 1 minute before reperfusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 10 ml of normal saline
Study: NCT00857454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone MD-Lotion
Description: 30 mg to 120 mg administered topically once daily for 60 days
Study: NCT03031184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01112254

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI±biopsy
Description: A MRI-guided or CT-guided preoperative biopsy will be performed in case of suspicious enhancement, multiple and large lesions (more than 3 cm for from the initial lesion), which is not viewed on the mammography or breast ultrasound. The surgery type will depends on the MRI +/- ± biopsy results.
Study: NCT00211263

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Clinical Intervention

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mood stabilizer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mood stabilizer
Study: NCT00245063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cediranib maleate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04077723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Englumafusp alfa
Description: Englumafusp alfa will be administered by intravenous (IV) infusion three-weekly (Q3W) in combination with a fixed dose of obinutuzumab (Part I) and in combination with a fixed dose of glofitamab (Part II and Part III).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Englumafusp alfa
Description: Englumafusp alfa will be administered by intravenous (IV) infusion three-weekly (Q3W) in combination with a fixed dose of obinutuzumab (Part I) and in combination with a fixed dose of glofitamab (Part II and Part III).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Englumafusp alfa
Description: Englumafusp alfa will be administered by intravenous (IV) infusion three-weekly (Q3W) in combination with a fixed dose of obinutuzumab (Part I) and in combination with a fixed dose of glofitamab (Part II and Part III).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: A fixed dose of obinutuzumab will be administered up to 7 days prior to the first dose of englumafusp alfa, then in combination with obinutuzumab Q3W (Part I).~A fixed dose of obinutuzumab will be administered up to 7 days prior to the first dose of englumafusp alfa or between Day -3 and -7 (Part II and Part III).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: A fixed dose of obinutuzumab will be administered up to 7 days prior to the first dose of englumafusp alfa, then in combination with obinutuzumab Q3W (Part I).~A fixed dose of obinutuzumab will be administered up to 7 days prior to the first dose of englumafusp alfa or between Day -3 and -7 (Part II and Part III).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: A fixed dose of obinutuzumab will be administered up to 7 days prior to the first dose of englumafusp alfa, then in combination with obinutuzumab Q3W (Part I).~A fixed dose of obinutuzumab will be administered up to 7 days prior to the first dose of englumafusp alfa or between Day -3 and -7 (Part II and Part III).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: A fixed dose of glofitamab will be administered Q3W in combination with englumafusp alfa in Part II and Part III

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: A fixed dose of glofitamab will be administered Q3W in combination with englumafusp alfa in Part II and Part III

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive IV tocilizumab as needed to treat cytokine release syndrome (CRS).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive IV tocilizumab as needed to treat cytokine release syndrome (CRS).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive IV tocilizumab as needed to treat cytokine release syndrome (CRS).
Study: NCT03545464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Placebo of cortancyl Oral Tablet 20mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cortancyl Oral Tablet
Description: Cortancyl oral Tablet 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine Oral Tablet
Description: Levocetirizine Oral Tablet 5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levocetirizine Oral Tablet
Description: Levocetirizine Oral Tablet 5 mg
Study: NCT02670304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: letrozole from the day of oocyte retrieval for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: aspirin from the day of oocyte retrieval for 5 days
Study: NCT00049764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03426046

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial Pulpotomy
Description: Partial removal of inflamed pulp tissue in cariously exposed teeth

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Partial Pulpotomy
Description: Partial removal of inflamed pulp tissue in cariously exposed teeth

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial Pulpotomy
Description: Partial removal of inflamed pulp tissue in cariously exposed teeth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pulp Capping Agents
Description: Biocompatible materials

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pulp Capping Agents
Description: Biocompatible materials

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pulp Capping Agents
Description: Biocompatible materials
Study: NCT04387279

Intervention type: OTHER
Intervention: Interview
Description: Surveys on medical use patterns and patient's perceptions about COVID-19
Study: NCT01597362

Intervention type: PROCEDURE
Group type: OTHER
Intervention: laparoscopy
Description: Trocar access in laparoscopy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopy
Description: The angle of the Veress needle insertion is 45 for non-obese women. After insertion of the needle, tests to determinate its correct positioning are: the double click test, the aspiration test, the handing drop test, serial intrabdominal gas pressure measurements.~The volume of CO2 inserted with the Veress needle depends on the intra-abdominal pressure. Adequate pneumoperitoneum should is determined by a pressure of 20 to 30 mm Hg and not by predetermined CO2 volume.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopy
Description: Direct insertion of the trocar is performed without prior pneumoperitoneum. Infra-umbilical skin incision is wide enough to accomodate the diameter of a sharp trocar/cannual system. The abdominal wall is elevated by pulling on, by hands, two towel clips placed 3 cm on either side of the umbilicus, and the trocar is inserted at a 90°angle.~On removal of the sharp trocar, the laparoscope is inserted to confirm the presence of omentum or bowel in the visual field.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopy
Description: A small incision, 1 cm long, is made through the skin of the lower edge of the umbilical fossa. The skin and the subcutaneous adipose tissues are retracted with the Zimmerman dissectors. The anterior rectus fascia is incised with the scalpel. The dissection with the Zimmerman valves allows the exposure of the peritoneum. After the peritoneum is incised, the trocar is inserted under direct vision. The laparoscope is introduced and insufflation is started. At the end of the procedure the fascial defect is closed.
Study: NCT03121690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: prednisone 40 mg/day for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: prednisone 40 mg/day for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: 5ml saline / day for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: 5ml saline / day for 7 days
Study: NCT02593539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemiralisib
Description: Participants will be administered nemiralisib
Study: NCT04091906

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral blood mononuclear cell apheresis
Description: Peripheral blood mononuclear cell donation for tumor immunotherapy study of UCAR-T cells
Study: NCT03396731

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: geko™ medical device
Description: The geko™ device, manufactured by Firstkind Ltd (High Wycombe, United Kingdom), is a small disposable, battery powered CE marked medical device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: geko™ medical device
Description: The geko™ device, manufactured by Firstkind Ltd (High Wycombe, United Kingdom), is a small disposable, battery powered CE marked medical device.
Study: NCT04856761

Intervention type: DRUG
Intervention: S-1
Description: S-1 was administered at a dose of 80-120 mg/day on 14 days of a tri-weekly cycle for 8 cycles.

Intervention type: DRUG
Intervention: Capecitabine
Description: Capecitabine was administered at a dose of 1250 mg/m² bid on 14 days of a tri-weekly cycle for 8 cycles.
Study: NCT01748383

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transplantation of BMMCs
Description: The wing of the ilium was punctured under the local anesthesia for receiving of autologous BMCs. 100 ml of bone marrow aspirate was taken. BMMCs were obtained by the method of the gradient centrifugation. Autologous BMMCs in the number 93±43 million transplantation by balloon catheter performed into IRA at once after stent implantation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transplantation of CD 133+ cells
Description: The wing of the ilium was punctured under the local anesthesia for receiving of autologous BMCs. 100 ml of bone marrow aspirate was taken. Autologous CD133 + cells were obtained by the method of the magnetic separation. Phenotyping of the transplanted cells was performed by the cytofluorimetry. Autologous CD 133+ BMCs in the number 5,7 (0,45;9,0) million transplantation by balloon catheter performed into IRA at once after stent implantation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stenting of IRA
Description: The only stent implantation
Study: NCT02609399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peramivir
Description: IV~Note: Subjects admitted to the hospital directly from the ED Enrollment Visit may receive more doses at the discretion of the treating physician.
Study: NCT00404729

Intervention type: DRUG
Group type: OTHER
Intervention: Citicoline
Description: Ten OAG patients will be untreated (NT-AOG, 10 eyes), while 20 OAG patients (T-AOG, 20 eyes) and 15 NION patients (T-NION, 14 eyes) were treated with Citicoline (oral treatment:1600 mg/die per 60 days)
Study: NCT03895138

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Glucommander Protocol (SGP)
Description: Subjects receive standard Glucommander-based insulin therapy from the clinical staff of U.Va.'s cardiothoracic ICU and follow manufacturer's guidelines for starting with an initial multiplier value of .05.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimized Glucommander (OGM)
Description: The experimental arm of the study involves treating subjects with a lower initial multiplier (.02 versus .05), a higher set of BG thresholds (140-180 mg/dl vs 120-160) in the first eight (8) hours of care for avoidance of hypoglycemia in that time period, and a requirement for consistent hourly-or-faster sampling of BG (as opposed to the Glucommander recommendation which is dependent on the trajectory of BG and can sometimes allow intervals of two hours between samples). After the eight (8) hours, the Glucommander is set back to the standard protocol for the entire duration of the subject's post-operative hospital stay.
Study: NCT00302640

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alinia (nitazoxanide)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alinia (nitazoxanide)
Study: NCT01390168

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Internet-administrated CBT-Treatment
Description: This intervention contains up to 6-10 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are prescribed following the diagnostic telephone interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist
Description: active waitlist
Study: NCT03289390

Intervention type: DRUG
Intervention: Acetaminophen
Description: Acetaminophen given at discretion of medical team for PDA treatment. Research team to evaluate pre and post laboratory values and echocardiograms.
Study: NCT01490203

Intervention type: DRUG
Intervention: Gd-EOB-DTPA
Description: 1. Gd-EOB-DTPA enhanced MRI will be obtained within 1 week before, and within 3 to 5 days after surgical resection of the liver.~2. Gd-EOB-DTPA will be administered intravenously with an amount of 0.1mL/kg, 1mL/sec injection rate, followed by saline infusion.

Intervention type: DRUG
Intervention: Gd-EOB-DTPA
Description: 1. Gd-EOB-DTPA enhanced MRI will be performed within 3 days of obtaining ICG R15 test.~2. Gd-EOB-DTPA will be administered intravenously with an amount of 0.1mL/kg, 1mL/sec injection rate, followed by saline infusion.

Intervention type: PROCEDURE
Intervention: MRI
Description: 1. Gd-EOB-DTPA enhanced MRI will be obtained within 1 week before, and within 3 to 5 days after surgical resection of the liver.~2. Multiphasic MRI including dynamic hepatocyte specific phase will be performed for evaluation of hepatic extraction fraction, with 25 phase dynamic MRI obtained until 30 minutes after contrast injection.

Intervention type: PROCEDURE
Intervention: MRI
Description: 1. Gd-EOB-DTPA enhanced MRI will be performed within 3 days of obtaining ICG R15 test.~2. Multiphasic MRI including dynamic hepatocyte specific phase will be performed for evaluation of hepatic extraction fraction, with 25 phase dynamic MRI obtained until 30 minutes after contrast injection.